A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

Mezzanotte-Sharpe J, ONeill A, Mayer IA, Arteaga CL, Yang XJ, Wagner LI, Cella D, Meropol NJ, Alpaugh RK, Saphner TJ, Swaney RE, Hoelzer KL, Gradishar WJ, Abramson VG, Sundaram PK, Jilani SZ, Perez EA, Lin NU, Jahanzeb M, Wolff AC, Sledge GW, Reid SA

Open source

DOI: 10.1007/s10549-024-07417-4
Published: 2024 Sep
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-024-07417-4,
  title = {A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).},
  author = {Mezzanotte-Sharpe J and ONeill A and Mayer IA and Arteaga CL and Yang XJ and Wagner LI and Cella D and Meropol NJ and Alpaugh RK and Saphner TJ and Swaney RE and Hoelzer KL and Gradishar WJ and Abramson VG and Sundaram PK and Jilani SZ and Perez EA and Lin NU and Jahanzeb M and Wolff AC and Sledge GW and Reid SA},
  year = {2024},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-024-07417-4},
  url = {https://doi.org/10.1007/s10549-024-07417-4}
}

RIS

TY  - JOUR
TI  - A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
AU  - Mezzanotte-Sharpe J
AU  - ONeill A
AU  - Mayer IA
AU  - Arteaga CL
AU  - Yang XJ
AU  - Wagner LI
AU  - Cella D
AU  - Meropol NJ
AU  - Alpaugh RK
AU  - Saphner TJ
AU  - Swaney RE
AU  - Hoelzer KL
AU  - Gradishar WJ
AU  - Abramson VG
AU  - Sundaram PK
AU  - Jilani SZ
AU  - Perez EA
AU  - Lin NU
AU  - Jahanzeb M
AU  - Wolff AC
AU  - Sledge GW
AU  - Reid SA
PY  - 2024
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-024-07417-4
UR  - https://doi.org/10.1007/s10549-024-07417-4
ER  -

APA

J, M., A, O., IA, M., CL, A., XJ, Y., LI, W., D, C., NJ, M., RK, A., TJ, S., RE, S., KL, H., WJ, G., VG, A., PK, S., SZ, J., EA, P., NU, L., M, J., AC, W., GW, S., & SA, R. (2024). A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).. Breast cancer research and treatment. https://doi.org/10.1007/s10549-024-07417-4

Source records

pubmed · retrieved 2026-09-26T23:53:39.173Z